Lingshan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lingshan Wang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Paul G. Kluetz
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
8 shared publications - Richard Pazdur
Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD
8 shared publications - Claudia P. Miller
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
7 shared publications - Diana Bradford
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
7 shared publications - Donna R. Rivera
Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD
7 shared publications - Harpreet Singh
Oncology Center of Excellence (OCE), US Food and Drug Administration, Silver Spring, MD
7 shared publications
Latest Publications
- 11 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF7
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ
On April 22, 2024, the U.S. FDA granted regular approval to nogapendekin alfa inbakicept-pmln (N-803) with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. Substantial evidence of effectiveness for this application was obtained from cohort A of the single-arm, multicenter QUILT-3.032 trial. Patients received N-803 400 μg administered intravesically with TICE BCG once a week for 6 weeks as induction therapy, a second induction course if complete response (CR) was not achieved at month 3, and maintenance N-803 with BCG weekly for 3 weeks at months 4, 7, 10, 13, and 19 (for a total of 15 maintenance doses). The major efficacy outcome measures were CR at any time [as defined by negative results for cystoscopy [with transurethral resection of bladder tumor (TURBT)/biopsies as applicable] per local investigator assessment and urine cytology] and duration of response. The CR rate in the 77-patient efficacy population, per FDA review, was 62% [95% confidence interval (CI), 51%–73%]. Of the 48 patients with a CR, 28 (58%; 95% CI, 26%–55%) and 19 (40%; 95% CI, 16%–36%) maintained a response for ≥12 months and ≥24 months, respectively. The most common adverse reactions were increased creatinine, dysuria, hematuria, urinary frequency, urinary urgency, and urinary tract infection. This article summarizes the data and FDA thought process supporting the approval of N-803 with BCG.
- 11 September 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF7
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ
On April 22, 2024, the U.S. FDA granted regular approval to nogapendekin alfa inbakicept-pmln (N-803) with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. Substantial evidence of effectiveness for this application was obtained from cohort A of the single-arm, multicenter QUILT-3.032 trial. Patients received N-803 400 μg administered intravesically with TICE BCG once a week for 6 weeks as induction therapy, a second induction course if complete response (CR) was not achieved at month 3, and maintenance N-803 with BCG weekly for 3 weeks at months 4, 7, 10, 13, and 19 (for a total of 15 maintenance doses). The major efficacy outcome measures were CR at any time [as defined by negative results for cystoscopy [with transurethral resection of bladder tumor (TURBT)/biopsies as applicable] per local investigator assessment and urine cytology] and duration of response. The CR rate in the 77-patient efficacy population, per FDA review, was 62% [95% confidence interval (CI), 51%–73%]. Of the 48 patients with a CR, 28 (58%; 95% CI, 26%–55%) and 19 (40%; 95% CI, 16%–36%) maintained a response for ≥12 months and ≥24 months, respectively. The most common adverse reactions were increased creatinine, dysuria, hematuria, urinary frequency, urinary urgency, and urinary tract infection. This article summarizes the data and FDA thought process supporting the approval of N-803 with BCG.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Distribution and Key Features of PIK3CA mutations and Response to Alpelisib within the Efficacy Population
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Distribution and Key Features of PIK3CA mutations and Response to Alpelisib within the Efficacy Population
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Distribution and Key Features of PIK3CA mutations and Response to Alpelisib within the Efficacy Population
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Distribution and Key Features of PIK3CA mutations and Response to Alpelisib within the Efficacy Population
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Laboratory Abnormalities Worsening from Baseline in ≥10% of Patients in EPIK-P1
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Laboratory Abnormalities Worsening from Baseline in ≥10% of Patients in EPIK-P1
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Laboratory Abnormalities Worsening from Baseline in ≥10% of Patients in EPIK-P1
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Laboratory Abnormalities Worsening from Baseline in ≥10% of Patients in EPIK-P1
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Data from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
On April 5, 2022, FDA granted accelerated approval to alpelisib for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Efficacy was evaluated using real-world data (RWD) from EPIK-P1 (NCT04285723), a single-arm clinical study in patients 2 years of age and older with severe or life-threatening PROS who received alpelisib as part of an expanded access program (EAP) for compassionate use. The primary endpoint was confirmed radiologic response rate at week 24 as determined by blinded independent central review (BICR), using volumetric-based criteria given the atypical growth pattern and irregular shape of PROS lesions. Radiologic response was defined as a ≥20% reduction from baseline in the sum of measurable target lesion volume in up to three lesions. Of the 37 patients in the efficacy population, 27% [95% confidence interval (CI), 14–44] had a radiologic response at week 24. Duration of response (DOR) was an additional efficacy outcome measure, and among responders, 60% had a response lasting ≥12 months. Furthermore, supportive clinical documentation suggested early signals of clinical benefit (i.e., improvement in PROS-related signs and symptoms). The most common (≥10%) adverse reactions were diarrhea, stomatitis, and hyperglycemia.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
On April 5, 2022, FDA granted accelerated approval to alpelisib for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Efficacy was evaluated using real-world data (RWD) from EPIK-P1 (NCT04285723), a single-arm clinical study in patients 2 years of age and older with severe or life-threatening PROS who received alpelisib as part of an expanded access program (EAP) for compassionate use. The primary endpoint was confirmed radiologic response rate at week 24 as determined by blinded independent central review (BICR), using volumetric-based criteria given the atypical growth pattern and irregular shape of PROS lesions. Radiologic response was defined as a ≥20% reduction from baseline in the sum of measurable target lesion volume in up to three lesions. Of the 37 patients in the efficacy population, 27% [95% confidence interval (CI), 14–44] had a radiologic response at week 24. Duration of response (DOR) was an additional efficacy outcome measure, and among responders, 60% had a response lasting ≥12 months. Furthermore, supportive clinical documentation suggested early signals of clinical benefit (i.e., improvement in PROS-related signs and symptoms). The most common (≥10%) adverse reactions were diarrhea, stomatitis, and hyperglycemia.
- Open Access
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Data from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
On April 5, 2022, FDA granted accelerated approval to alpelisib for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Efficacy was evaluated using real-world data (RWD) from EPIK-P1 (NCT04285723), a single-arm clinical study in patients 2 years of age and older with severe or life-threatening PROS who received alpelisib as part of an expanded access program (EAP) for compassionate use. The primary endpoint was confirmed radiologic response rate at week 24 as determined by blinded independent central review (BICR), using volumetric-based criteria given the atypical growth pattern and irregular shape of PROS lesions. Radiologic response was defined as a ≥20% reduction from baseline in the sum of measurable target lesion volume in up to three lesions. Of the 37 patients in the efficacy population, 27% [95% confidence interval (CI), 14–44] had a radiologic response at week 24. Duration of response (DOR) was an additional efficacy outcome measure, and among responders, 60% had a response lasting ≥12 months. Furthermore, supportive clinical documentation suggested early signals of clinical benefit (i.e., improvement in PROS-related signs and symptoms). The most common (≥10%) adverse reactions were diarrhea, stomatitis, and hyperglycemia.
- 5 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
On April 5, 2022, FDA granted accelerated approval to alpelisib for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Efficacy was evaluated using real-world data (RWD) from EPIK-P1 (NCT04285723), a single-arm clinical study in patients 2 years of age and older with severe or life-threatening PROS who received alpelisib as part of an expanded access program (EAP) for compassionate use. The primary endpoint was confirmed radiologic response rate at week 24 as determined by blinded independent central review (BICR), using volumetric-based criteria given the atypical growth pattern and irregular shape of PROS lesions. Radiologic response was defined as a ≥20% reduction from baseline in the sum of measurable target lesion volume in up to three lesions. Of the 37 patients in the efficacy population, 27% [95% confidence interval (CI), 14–44] had a radiologic response at week 24. Duration of response (DOR) was an additional efficacy outcome measure, and among responders, 60% had a response lasting ≥12 months. Furthermore, supportive clinical documentation suggested early signals of clinical benefit (i.e., improvement in PROS-related signs and symptoms). The most common (≥10%) adverse reactions were diarrhea, stomatitis, and hyperglycemia.
- 25 August 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (1) , 23-28
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
On April 5, 2022, FDA granted accelerated approval to alpelisib for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Efficacy was evaluated using real-world data (RWD) from EPIK-P1 (NCT04285723), a single-arm clinical study in patients 2 years of age and older with severe or life-threatening PROS who received alpelisib as part of an expanded access program (EAP) for compassionate use. The primary endpoint was confirmed radiologic response rate at week 24 as determined by blinded independent central review (BICR), using volumetric-based criteria given the atypical growth pattern and irregular shape of PROS lesions. Radiologic response was defined as a ≥20% reduction from baseline in the sum of measurable target lesion volume in up to three lesions. Of the 37 patients in the efficacy population, 27% [95% confidence interval (CI), 14–44] had a radiologic response at week 24. Duration of response (DOR) was an additional efficacy outcome measure, and among responders, 60% had a response lasting ≥12 months. Furthermore, supportive clinical documentation suggested early signals of clinical benefit (i.e., improvement in PROS-related signs and symptoms). The most common (≥10%) adverse reactions were diarrhea, stomatitis, and hyperglycemia.
- 25 August 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (1) , 23-28
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
On April 5, 2022, FDA granted accelerated approval to alpelisib for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Efficacy was evaluated using real-world data (RWD) from EPIK-P1 (NCT04285723), a single-arm clinical study in patients 2 years of age and older with severe or life-threatening PROS who received alpelisib as part of an expanded access program (EAP) for compassionate use. The primary endpoint was confirmed radiologic response rate at week 24 as determined by blinded independent central review (BICR), using volumetric-based criteria given the atypical growth pattern and irregular shape of PROS lesions. Radiologic response was defined as a ≥20% reduction from baseline in the sum of measurable target lesion volume in up to three lesions. Of the 37 patients in the efficacy population, 27% [95% confidence interval (CI), 14–44] had a radiologic response at week 24. Duration of response (DOR) was an additional efficacy outcome measure, and among responders, 60% had a response lasting ≥12 months. Furthermore, supportive clinical documentation suggested early signals of clinical benefit (i.e., improvement in PROS-related signs and symptoms). The most common (≥10%) adverse reactions were diarrhea, stomatitis, and hyperglycemia.